# Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin

Study · id `cardio:ct-nct01613729` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01613729](<https://clinicaltrials.gov/study/NCT01613729>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01613729

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 2000 participants.

## Technical summary

Registry record NCT01613729. Randomized; no masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 2000 participants (planned count; ClinicalTrials.gov record NCT01613729, source copy `cardio:ctgov-nct01613729-2012-09-25`, retrieved 2026-10-31)
- Start date: 2012-07 (registry gives no type) (ClinicalTrials.gov record NCT01613729, source copy `cardio:ctgov-nct01613729-2012-09-25`, retrieved 2026-10-31)
- Primary completion: 2013-07 (anticipated) (ClinicalTrials.gov record NCT01613729, source copy `cardio:ctgov-nct01613729-2012-09-25`, retrieved 2026-10-31)
- Completion: 2013-12 (anticipated) (ClinicalTrials.gov record NCT01613729, source copy `cardio:ctgov-nct01613729-2012-09-25`, retrieved 2026-10-31)
- Countries: Bangladesh (ClinicalTrials.gov record NCT01613729, source copy `cardio:ctgov-nct01613729-2012-09-25`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01613729-2012-09-25`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin
- Acronym: Cor16
- Condition: Dyslipidemia
- Intervention (Drug): Rosuvastatin 5 mg
- Intervention (Drug): Rosuvastatin 10 mg
- Lead sponsor: D16 Pharma & Biotec Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
- Collaborator class: OTHER
- Collaborator: Dhaka Medical College
- Collaborator class: OTHER
- Collaborator: National Institute of Cardiovascular Diseases
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Rosuvastatin (`cardio:rosuvastatin`)
- Registry intervention is a member of this class by a sourced record link: Statins (`cardio:statins`)

## Provenance

Content hash: 728300aae1d375876831ac30e0b1e22a445a4a97eb7a878b8f632e32d9c9f505
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
